NCT05104125

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Multi-dose Study to Evaluate Safety and Efficacy of ASC40 Tablets in Subjects With Moderate to Severe Acne Vulgaris.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Ascletis Pharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

This is a phase2, randomized, double-blind, multi-center, multi-dose and placebo parallel controlled design. The subjects in the study group were given double-blind drugs, and they were taken (orally) after dinner every day according to the requirements of clinical trial scheme.

Conditions

• Acne Vulgaris

Interventions

Type	Name	Description
DRUG	ASC40 25mg	25mg of ASC40 orally once daily for 12 weeks.
DRUG	ASC40 50mg	50mg of ASC40 orally once daily for 12 weeks.
DRUG	ASC40 75mg	75mg of ASC40 orally once daily for 12 weeks.
DRUG	Placebo	Placebo orally once daily for 12 weeks.

Timeline

• Start date: 2022-01-12
• Primary completion: 2023-04-10
• Completion: 2023-04-10
• First posted: 2021-11-02
• Last updated: 2025-05-16

Locations

1 site across 1 country: China